Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation

Liver Transplantation

Volumn 14, Issue 7, 2008, Pages 1044-1047

  Takada, Yasutsugu ^a   Ito, Takashi ^a   Ueda, Yoshihide ^a   Haga, Hironori ^a   Egawa, Hiroto ^a   Tanaka, Koichi ^b   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE FILTRATION PLASMAPHERESIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FEVER; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR LIVER TRANSPLANTATION; MALAISE; MALE; NONHUMAN; PLASMAPHERESIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMAPHERESIS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN; VIRAL LOAD;

EID: 48949120179     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21441     Document Type: Article

References (12)

1. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003;9:S23-S34.
2. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
3. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhous R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830-836.
4. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12:1192-1204.
5. Shiffman ML. Treating chronic hepatitis C virus after liver transplantation: balancing the risks against the chance for success. Liver Transpl 2007;13:1088-1091.
6. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transplant 2006;6:2348-2355.
7. Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13:1100-1108.
8. Takada Y, Haga H, Ito T, Nabeshima. M, Ogawa K, Kasahara M, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation 2006;81:350-354.
9. Iwai A, Maruzawa H, Takada Y, Egawa H, Ikeda K, Nabeshima M, et al. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection. J Viral Hepat 2006; 13:523-531.
10. Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, et al. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 2007;37:701-710.
11. Taniguchi M, Furukawa H, Shimamura T, Suzuki T, Yamashita K, Todo S. Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C. Transplantation 2006;81:1747-1749.
12. Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2006;12:1067-1076.